Literature DB >> 24486123

Midline versus transverse incision for cesarean delivery in low-income countries.

Nanna Maaløe1, Anna J M Aabakke2, Niels J Secher3.   

Abstract

While transverse incision is the recommended entry technique for cesarean delivery in high-income countries, it is our experience that midline incision is still used routinely in many low-income settings. Accordingly, international guidelines lack uniformity on this matter. Although evidence is limited, the literature suggests important advantages of the transverse incision, with lower risk of long-term disabilities such as wound disruption and hernia. Also, potential extra time spent on this incision appears not to impact neonatal outcome. Therefore, we suggest that it is time for a change in guidelines for low-income settings in which resources are limited for treating complications that may be life threatening.
Copyright © 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adverse effects; Cesarean delivery; Delivery; Methods; Midline; Obstetric; Transverse; Women

Mesh:

Year:  2014        PMID: 24486123     DOI: 10.1016/j.ijgo.2013.09.030

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

Review 1.  Minimally Invasive Techniques for Bladder Reconstruction.

Authors:  Tony Nimeh; Sean Elliott
Journal:  Curr Urol Rep       Date:  2018-04-13       Impact factor: 3.092

2.  Incidence of incisional hernia after cesarean delivery: a register-based cohort study.

Authors:  Anna J M Aabakke; Lone Krebs; Steen Ladelund; Niels J Secher
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

3.  Association between surgical technique, adhesions and morbidity in women with repeat caesarean section: a retrospective study in a rural hospital in Western Tanzania.

Authors:  R Mooij; I H Mwampagatwa; J van Dillen; J Stekelenburg
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-04       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.